Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
23 pending office actions • 12 clients • 21 examiners • 13 art units • 0 of 23 (0%) have an AI response strategy ready
PROSKAUER ROSE LLP has a substantial history in Biotechnology & Pharmaceuticals, managing 2892 career applications. The firm has achieved a resolved allowance rate of 71.41 percent. Prosecution in this complex field requires an average of 3.6 office actions per allowance. There are 19 pending office actions currently under management.
The 71.41 percent allowance rate across 2892 career applications reflects the challenging nature of Biotechnology & Pharmaceuticals prosecution. The 3.6 office actions per allowance indicate that the firm frequently engages in multiple rounds of examination to reach a resolution. These metrics offer a realistic view of the effort and persistence required to secure patent grants in the life sciences.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (9%) |
| §112 only | 3 (13%) |
| Double-patenting only | 1 (4%) |
| Double-patenting + other | 8 (35%) |
| Multi-statute (no §101) | 9 (39%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SWIFT, CANDICE LEE | 2 | 57.5% | +36.0% |
| DAVIS, RUTH A | 2 | 60.8% | +31.1% |
| ESSEX, LAURA ANN | 1 | 60.5% | +35.2% |
| DUFFY, PATRICIA ANN | 1 | 52.9% | +33.9% |
| GANGLE, BRIAN J | 1 | 76.7% | +14.7% |
| MOU, LIYUAN | 1 | 42.9% | +59.0% |
| JACKSON-TONGUE, LAKIA J | 1 | 69.0% | +20.8% |
| GRASER, JENNIFER E | 1 | 76.7% | +23.4% |
| OGUNBIYI, OLUWATOSIN A | 1 | 63.7% | +41.4% |
| HUDSON, AMY ROSE | 1 | 74.9% | +11.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18258914 | HOMOGENEOUS BIOPOLYMER SUSPENSIONS, PROCESSES FOR MAKING SAME AND USES THEREOF | BABSON, NICOLE PLOURDE | 79d overdue |
| 19086136 | FIVE-MEMBERED-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | MOU, LIYUAN | 9d |
| 17759674 | TREATMENT OF SKIN CONDITIONS | DAVIS, RUTH A | 40d |
| 19309183 | CHIMERIC NEUROTOXINS | DUFFY, PATRICIA ANN | — |
| 18914188 | TREATMENT OF AUTONOMIC DISORDERS WITH BOTULINUM TOXIN | JACKSON-TONGUE, LAKIA J | — |
| 18711047 | TREATMENT OF VISCERAL PAIN | GRASER, JENNIFER E | — |
| 18599808 | FATTY ACID CONJUGATES OF NUCLEIC ACIDS | HUDSON, AMY ROSE | — |
| 18003570 | CONTROLLING OPERATION OF A BIOREACTOR VESSEL | CLARKE, TRENT R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19086136 | FIVE-MEMBERED-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | MOU, LIYUAN | 9d |
| 18096899 | TREATMENT OF MODERATE TO VERY SEVERE GLABELLAR LINES AND LATERAL CANTHAL LINES | DAVIS, RUTH A | 34d |
| 17759674 | TREATMENT OF SKIN CONDITIONS | DAVIS, RUTH A | 40d |
| 19532470 | TREATMENT OF RECURRENT PERICARDITIS BY DELIVERY OF ANTI-INTERLEUKIN-1 RECEPTOR ANTIBODY | ESSEX, LAURA ANN | — |
| 19309183 | CHIMERIC NEUROTOXINS | DUFFY, PATRICIA ANN | — |
| 19189864 | LIQUID NEUROTOXIN FORMULATION STABILIZED WITH TRYPTOPHAN OR TYROSINE | GANGLE, BRIAN J | — |
| 18914188 | TREATMENT OF AUTONOMIC DISORDERS WITH BOTULINUM TOXIN | JACKSON-TONGUE, LAKIA J | — |
| 18711047 | TREATMENT OF VISCERAL PAIN | GRASER, JENNIFER E | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Ipsen | 12 |
| Kiniksa Pharmaceuticals, GmbH | 1 |
| Hangzhou Polymed Biopharmaceuticals | 1 |
| Guardian Therapeutics, LLC | 1 |
| Theseus Pharmaceuticals, Inc. | 1 |
| Zenyth Operations Pty. Ltd. | 1 |
| Otsuka | 1 |
| 11584022 CANADA INC. | 1 |
| Imcheck Therapeutics SAS | 1 |
| VISTERRA, INC. | 1 |
| Praeventix, LLC | 1 |
| Chimagen Biosciences, Ltd. | 1 |
| Art Unit | Apps |
|---|---|
| 1645 | 3 |
| 1675 | 2 |
| 1657 | 2 |
| 1651 | 2 |
| 1699 | 2 |
| 1628 | 1 |
| 1629 | 1 |
| 1619 | 1 |
| 1641 | 1 |
| 1643 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19532470 | TREATMENT OF RECURRENT PERICARDITIS BY DELIVERY OF ANTI-INTERLEUKIN-1 RECEPTOR ANTIBODY | Kiniksa Pharmaceuticals, GmbH | ESSEX, LAURA ANN | 1675 | §103 | Non-Final OA | — | Pending | Feb 06, 2026 |
| 19309183 | CHIMERIC NEUROTOXINS | Ipsen Biopharm Limited | DUFFY, PATRICIA ANN | 1645 | §102§103Other | Non-Final OA | — | Pending | Aug 25, 2025 |
| 19189864 | LIQUID NEUROTOXIN FORMULATION STABILIZED WITH TRYPTOPHAN OR TYROSINE | Ipsen Biopharm Limited | GANGLE, BRIAN J | §112DP | Non-Final OA | — | Pending | Apr 25, 2025 | |
| 19086136 | FIVE-MEMBERED-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | Hangzhou Polymed Biopharmaceuticals, Inc. | MOU, LIYUAN | 1628 | §103§112Other | Final Rejection | 9d | Pending | Mar 21, 2025 |
| 18914188 | TREATMENT OF AUTONOMIC DISORDERS WITH BOTULINUM TOXIN | Ipsen Biopharm Limited | JACKSON-TONGUE, LAKIA J | §102§103§112 | Non-Final OA | — | Pending | Oct 13, 2024 | |
| 18711047 | TREATMENT OF VISCERAL PAIN | Ipsen Biopharm Limited | GRASER, JENNIFER E | 1645 | §103§112 | Non-Final OA | — | Pending | May 16, 2024 |
| 18711074 | TREATMENT OF PAIN | Ipsen Biopharm Limited | OGUNBIYI, OLUWATOSIN A | 1645 | §102§103DP | Non-Final OA | — | Pending | May 16, 2024 |
| 18599808 | FATTY ACID CONJUGATES OF NUCLEIC ACIDS | Guardian Therapeutics, LLC | HUDSON, AMY ROSE | §102§103§112 | Non-Final OA | — | Pending | Mar 08, 2024 | |
| 18690479 | Modified Bont/A for Use in the Treatment of a Disorder Affecting an Eyelid Muscle of a Subject | Ipsen Biopharm Limited | SWIFT, CANDICE LEE | 1657 | §103§112DP | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18690378 | Modified Bont/A for Use in the Treatment of Cervical Dystonia | Ipsen Biopharm Limited | SWIFT, CANDICE LEE | 1657 | §103§112DP | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18506625 | MACROCYCLIC COMPOUNDS AND USES THEREOF | Theseus Pharmaceuticals, Inc. | SHOWALTER, ALEXANDER KEITH | 1629 | §112 | Non-Final OA | 12d | Pending | Nov 10, 2023 |
| 18499051 | ANTIBODY MOLECULE FOR HUMAN GM-CSF RECEPTOR ALPHA | Zenyth Operations Pty. Ltd. | NATARAJAN, MEERA | §112 | Non-Final OA | — | Pending | Oct 31, 2023 | |
| 18552457 | CATALYTICALLY INACTIVE CLOSTRIDIAL NEUROTOXINS FOR THE TREATMENT OF PAIN & INFLAMMATORY DISORDERS | Ipsen Biopharm Limited | PAGUIO FRISING, MICHELLE F | 1651 | §102§103DP | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18466911 | PD-1 AGONIST ANTIBODIES | Otsuka Pharmaceutical Co., Ltd. | DONOGHUE, BRITTNEY ERIN | 1675 | §112 | Non-Final OA | — | Pending | Sep 14, 2023 |
| 18258914 | HOMOGENEOUS BIOPOLYMER SUSPENSIONS, PROCESSES FOR MAKING SAME AND USES THEREOF | 11584022 Canada Inc. | BABSON, NICOLE PLOURDE | 1619 | §102§103§112Other | Final Rejection | 79d overdue | Pending | Jun 22, 2023 |
| 18183588 | SELECTION OF RESPONDERS FOR ANTI-BTN3A TREATMENT | Imcheck Therapeutics SAS | ROONEY, NORA MAUREEN | 1641 | §112DP | Non-Final OA | — | Pending | Mar 14, 2023 |
| 18167529 | METHODS OF USING INTERLEUKIN-2 AGENTS | VISTERRA, INC. | CHATTIN, AMY MARIE | 1643 | §103 | Non-Final OA | — | Pending | Feb 10, 2023 |
| 18096899 | TREATMENT OF MODERATE TO VERY SEVERE GLABELLAR LINES AND LATERAL CANTHAL LINES | Ipsen Biopharm Limited | DAVIS, RUTH A | 1699 | §112DPOther | Final Rejection | 34d | Pending | Jan 13, 2023 |
| 18003570 | CONTROLLING OPERATION OF A BIOREACTOR VESSEL | Ipsen Biopharm Limited | CLARKE, TRENT R | 1651 | §102§103§112 | Non-Final OA | — | Pending | Dec 28, 2022 |
| 18003489 | TREATMENT OF POST-OPERATIVE SURGICAL PAIN | Ipsen Biopharm Limited | RAGHU, GANAPATHIRAM | 1652 | §102§103§112 | Final Rejection | — | Pending | Dec 27, 2022 |
| 17759674 | TREATMENT OF SKIN CONDITIONS | Ipsen Biopharm Limited | DAVIS, RUTH A | 1699 | §102§103§112Other | Non-Final OA | 40d | Pending | Jul 28, 2022 |
| 17776533 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | Praeventix, LLC | RICCI, CRAIG D | 1611 | DP | Final Rejection | 9d | Pending | May 12, 2022 |
| 15733195 | COVALENT MULTI-SPECIFIC ANTIBODIES | Chimagen Biosciences, Ltd. | DEBERRY, REGINA M | 1647 | §103DP | Non-Final OA | — | Pending | Jun 08, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial